<SEC-DOCUMENT>0001193125-22-089868.txt : 20220330
<SEC-HEADER>0001193125-22-089868.hdr.sgml : 20220330
<ACCEPTANCE-DATETIME>20220330163111
ACCESSION NUMBER:		0001193125-22-089868
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20220330
DATE AS OF CHANGE:		20220330
EFFECTIVENESS DATE:		20220330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-263983
		FILM NUMBER:		22786920

	BUSINESS ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>d268810ds8.htm
<DESCRIPTION>S-8
<TEXT>
<HTML><HEAD>
<TITLE>S-8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on March&nbsp;30, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">S-8</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">84-1475642</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Houston, TX</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>77054</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Full title of the plan) </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kevin S. Boyle, Sr. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Houston, TX 77054 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(346) <FONT
STYLE="white-space:nowrap">355-4099</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address and telephone number of agent for service) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Melinda Lackey</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Senior Vice President, Legal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Houston, TX 77054</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(346) <FONT
STYLE="white-space:nowrap">355-4099</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Brian K. Rosenzweig</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lilit Kazangyan</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Covington&nbsp;&amp; Burling LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>620 Eighth Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New
York, NY 10018</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">841-1000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE; INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM
<FONT STYLE="white-space:nowrap">S-8</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-241698)</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Registration Statement is being
filed by Alaunos Therapeutics, Inc. (the &#147;registrant&#148;) for the purpose of registering additional securities of the same class as other securities for which a registration statement filed on Form <FONT STYLE="white-space:nowrap">S-8</FONT>
relating to the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (the &#147;2020 Plan&#148;) is already effective. Pursuant to General Instruction E to Form <FONT STYLE="white-space:nowrap">S-8,</FONT> we incorporate by reference into this
Registration Statement the contents of the registration statement that we filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312520212035/d43260ds8.htm">Form <FONT STYLE="white-space:nowrap">S-8</FONT></A> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-241698)</FONT> with the Securities and Exchange Commission (the &#147;SEC&#148;) on August&nbsp;6, 2020 in its entirety and including exhibits thereto, relating to the registration of 5,750,000 shares of our
common stock, par value $0.001 per share, authorized for issuance under the 2020 Plan. This Registration Statement provides for the registration of an additional 15,250,000 shares of common stock to be issued under the 2020 Plan. 12,191,545 of these
shares represent the remaining shares of common stock reserved for issuance under the 2020 Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;3. Incorporation of Documents by Reference. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-33038)</FONT> previously filed with the SEC are hereby incorporated by reference:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registrant&#146;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;30, 2022 (the &#147;2021 Annual Report&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other reports filed with the SEC pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), since the end of the fiscal year covered by the Company&#146;s 2021 Annual Report; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of the Company&#146;s Common Stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_7.htm">Exhibit&nbsp;4.7
</A> to the 2021 Annual Report, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All reports
and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities registered have been sold or which deregisters
all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents, except as to specific sections of such statements as set forth
therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless expressly incorporated into this Registration Statement, a report furnished on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (or any
portion thereof so furnished) prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall
be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such
statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;6. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant is incorporated under the laws of the State of Delaware. Subsection (a)&nbsp;of Section&nbsp;145 of the General Corporation Law of the State of
Delaware (&#147;DGCL&#148;), empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or
investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal
action or proceeding, had no reasonable cause to believe the person&#146;s conduct was unlawful. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsection (b)&nbsp;of Section&nbsp;145 of the DGCL empowers a corporation to indemnify any person who was
or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities
set forth above, against expenses (including attorneys&#146; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person
reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case,
such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the
defense of any action, suit or proceeding referred to in subsections (a)&nbsp;and (b) of Section&nbsp;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#146; fees)
actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&nbsp;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification
provided for by Section&nbsp;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#146;s heirs, executors
and administrators. Section&nbsp;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out
of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&nbsp;145. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL provides that a corporation&#146;s certificate of incorporation may contain a provision eliminating or limiting the
personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&nbsp;for any breach of
the director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL or
(iv)&nbsp;for any transaction from which the director derived an improper personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant&#146;s amended and restated certificate of
incorporation provides for indemnification of the Registrant&#146;s directors to the maximum extent permitted by applicable law, and the Registrant&#146;s bylaws, as amended, provide for indemnification of the Registrant&#146;s directors, officers,
employees and other agents to the maximum extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant has entered into indemnification agreements with the Registrant&#146;s
directors, whereby the Registrant has agreed to indemnify the Registrant&#146;s directors to the fullest extent permitted by the DGCL, including advancement of expenses incurred in legal proceedings to which the director was, or is threatened to be
made, a party by reason of the fact that (i)&nbsp;such director is or was a director of the Registrant, (ii)&nbsp;such director acted while a director, officer, employee or agent of the Registrant, or (iii)&nbsp;such director was serving at the
request of the Registrant as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. At present, there is no pending litigation or proceeding involving a director
of the Registrant regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant maintains a directors&#146; and officers&#146; liability insurance policy that indemnifies the Registrant&#146;s directors and officers against
various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his capacity as such. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;8. EXHIBITS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000114420406016919/v041381_ex3-1.htm">Amended and Restated Certificate of Incorporation, and all amendments thereto (incorporated by reference to Exhibit 3.1 to the registrant&#146;s
 Annual Report on Form 10-K, File No. 001-33038, filed March 30, 2022). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312516640603/d220092dex31.htm">Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 preferred stock, as filed with the Delaware Secretary of State
 on July&nbsp;1, 2016 (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K/A,</FONT> SEC File <FONT STYLE="white-space:nowrap">No.&nbsp;001-33038,</FONT> filed July&nbsp;1,
2016). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312520250711/d42031dex31.htm">Amended and Restated Bylaws of the Registrant, dated
 as of September 21, 2020 (incorporated by reference to Exhibit&nbsp;3.1 to the Registrant&#146;s Current Report on Form 8-K, SEC File No. 001-33038, filed September 22, 2020). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000114420405031725/v026661_ex4-1.htm">Specimen common stock certificate (incorporated by reference to Exhibit 4.1 to the registrant&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">SB-2</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-129020)</FONT> filed with the Commission on October&nbsp;14, 2005 and incorporated herein by reference). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d268810dex51.htm">Opinion of Covington&nbsp;&amp; Burling LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d268810dex231.htm">Consent of RSM US LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d268810dex51.htm">Consent of Covington&nbsp;&amp; Burling LLP (included in Exhibit 5.1 and incorporated herein by reference). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on the signature page of this Registration Statement). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312520184639/d862521dex101.htm">ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the registrant&#146;s Current Report on Form
 <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-33038)</FONT> filed with the Commission on June&nbsp;29, 2020 and incorporated herein by reference). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d268810dexfilingfees.htm">Filing Fee Table</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Filed herewith</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-8</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, Texas, on the 30th
day of March, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Alaunos Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kevin S. Boyle, Sr.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin S. Boyle, Sr. and Michael Wong, jointly and
severally, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution, for him or her, and in his or her name, place
and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents full power and authority to do and perform each and every act and thing requisite or
necessary to be done in and about the premises hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or his substitute or substitutes, may lawfully
do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by
the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Signature</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Date</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Principal Executive Officer and Principal Financial Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;30, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Wong</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Wong</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Finance</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Principal
Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;30, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher Bowden</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christopher Bowden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;30, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Huang</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James Huang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;30, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert W. Postma</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert W. Postma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;30, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mary Thistle</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mary Thistle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;30, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaime Vieser</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jaime Vieser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;30, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Holger Weis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Holger Weis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;30, 2022</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d268810dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g268810dsp004.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March&nbsp;30, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8030 El Rio Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston, Texas 77054 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Alaunos Therapeutics, Inc., a Delaware corporation (the &#147;<I>Company</I>&#148;), in connection with the
registration by the Company under the Securities Act of 1933, as amended (the &#147;<I>Act</I>&#148;) of 15,250,000 shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<I>Shares</I>&#148;), issuable under the ZIOPHARM
Oncology, Inc. 2020 Equity Incentive Plan, as amended (the &#147;<I>Plan</I>&#148;), pursuant to the registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> filed with the Securities and Exchange Commission on the date hereof
(such registration statement is herein referred to as the &#147;<I>Registration Statement</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reviewed the Registration
Statement and such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion. We have assumed that all signatures are genuine, that all documents
submitted to us as originals are authentic, and that all copies of documents submitted to us conform to the originals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied as
to certain matters on information obtained from public officials, officers of the Company, and other sources believed by us to be responsible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when issued and sold in accordance with the
Plan, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to Shares issued pursuant to certain deferred payment arrangements under the Plan, which will be fully paid and
nonassessable when such deferred payments are made in full). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are members of the bar of the State of New York. We do not express any
opinion herein on any laws other than the Delaware General Corporation Law and reported judicial decisions interpreting such law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g268810dsp005.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement.
In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Covington&nbsp;&amp; Burling LLP</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d268810dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> of Alaunos Therapeutics, Inc.
of our report dated March&nbsp;30, 2022, relating to the financial statements of Alaunos Therapeutics, Inc. and its subsidiaries, appearing in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Alaunos Therapeutics, Inc. for
the year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ RSM US LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;30, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>d268810dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF FILING FEE TABLE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos
Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1 - Newly Registered Securities </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt">Security&nbsp;Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Security</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Class</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Calculation</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Rule</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Amount</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">to be</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Registered (1)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Proposed</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Maximum</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offering</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Price&nbsp;Per</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Proposed</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Maximum</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Aggregate</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offering</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Price</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Amount of</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Registration</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Equity</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Common Stock, par value<BR>$0.001 per share, to be<BR>issued under the<BR>Registrant&#146;s 2020
Equity<BR>Incentive Plan</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Rules<BR>457(c)<BR>and<BR>457(h)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">12,191,545(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$0.64(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$7,802,588.80</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$92.70 per<BR>$1,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$723.30</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Equity</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Common Stock, par value<BR>$0.001 per share, to be<BR>issued under the<BR>Registrant&#146;s 2020
Equity<BR>Incentive Plan</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Rule<BR>457(h)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">3,058,455(4)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$1.48(5)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$4,526,513.40</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">92.70 per<BR>$1,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$419.61</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Total
Offering Amounts</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$12,329,102.20</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$1,142.91</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Total
Fee Offsets (6)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Net
Fee Due</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$1,142.91</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), this
registration statement shall be deemed to cover any additional shares of common stock that may become issuable under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan from time to time by reason of any stock dividend, stock split,
recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of the Registrant&#146;s common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 12,191,545 shares reserved for future issuance under the Registrant&#146;s 2020 Equity Incentive
Plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated in accordance with Rule 457(c) and (h)&nbsp;under the Securities Act solely for the purpose of
calculating the registration fee on the basis of $0.64, which was the average of the high and low prices of the Registrant&#146;s common stock as reported on The Nasdaq Global Select Market on March&nbsp;25, 2022. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares of common stock underlying option awards granted and outstanding, but not registered, under
the Registrant&#146;s 2020 Equity Incentive Plan, as of March&nbsp;29, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated in accordance with Rule 457(h) under the Securities Act solely for the purpose of calculating the
registration fee on the basis of $1.48, which is weighted-average exercise price for options outstanding, but not registered, under the 2020 Equity Incentive Plan, as of March&nbsp;29, 2022. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Registrant does not have any fee offsets. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g268810dsp004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g268810dsp004.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M!T7AS56UWPUIFK-"(6O;:.<QALA-R@XSWZT := !0 4 % !0 4 % !0 4 %
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M$$<<:]%4#  _"@">@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M2%_-4$G>X*@ C<0,9X+<\C  VP\-Q66G_P!FF^N9]-6,PQVTA7"1D8VY #$
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M +OB35)=%\/W>H01K)+"H*J^<$E@.<<]Z .2NOB%>6^E6UT;.W5]]PMP")6
M$6W^ZI*;@P.6&%SR: -YO$LJ:BUD]O&D_P!LA@6(OEBCQAV;'?'SCCCY30!1
M3QE>/IVH2BQ@-W;2QA81-G]V[$!LXP_"DC:23@C /4 =#XMNKWQ%IUE9QVQL
M[FRM[MI2LA)$AD&%.!CA.-P!YZ"@"TWB>9_"<>JV\$,MTS*IA\P#;EL$^IP
M3@<G'% &YIMZFHZ7:7L90I<1+*"A)7!&>,@''U /L* ,+Q+XEN]#NCY,5K)!
M!:FYE660I)( V-L?!!;T!ZG XS0!(GB9VUDZ:8HQ+_:1M-N[YO+^S^=OQ^GI
M0!B:)\0;B]\-WVI7ME&DT%I#<11Q;OWK2[@B8(S]X 9'7/M0!MZ1XG.JG2%$
M*JUW'-YXYS%)$55E&><9)Z]L'O0!T,C>7$[ ?=!- '"0^,]:_P"$6L]6GLH(
MWO)8UC403MM5HRY.T LW3^$&@"W<>.OL\.@226:K]O19KD*Y<6\3$*K9 [LP
M.3CY5?N,4 20^,Y6\51:'-8^69KZ2WAFR2LB)"SL?9@RJ"#V8$=\ &=;^/[V
M^\*G5K:QC2?=9Q"WE5]^Z8IEMO79\_RXSG:?I0!JR>*+NRAD2^@@2Y%G'/&O
MS)YCM(RE &YX^3CKEJ (;+Q7J%[XEOM'BM8 R&<0NPD7'EX&YB1M8%F4$*<C
M/- &QX9U"_U71EO-1CMTE>1@JP%L!0=O.>^0?TH GU[54T70[W4&:,-!!)(B
MR-M#LJ%MOZ4 8=YXMN+;6'MQ;VQMX;FWM9(VE(G=IMF'1<<J-_X[7].0!+3Q
ML)-8>TNK.2UMH4OGEN9%(0K;RA,J>_!)/I0!6@\=W4^@QWL>DN]\MZMO+9 E
M7",-X*Y RVS''0L",]Z (+CXC-#I<6J162S:?)'>2&9"?D$4OEQL1C.UN,G^
M'.>@. #5MO$M[/XLNM-,5NEG; ;G(;<<Q*_WONCEN_84 9LGCF__ +%M;A+.
MW6]DOA:R0Y=Q'^Y:7J!\QPH&5)'.<]@ 6E\;-):13);Q!Y[>QFAC,A)<W$A1
M@.!G;CTH AB\<W27>LI-IXEBL(;N=1$'1B(9"@'S#:^[!Y4D+C!ZB@#<\/:X
MVK"[AG-O]IM7"O\ 9V9D(89!!(&>_(ZXSQG  -N@ H * "@ H * "@#B?'>J
M:CIKA[2X$<*64TCKYIC<$,F'C[2,N3B,X!SR1D9 &S:B(/'4.VXGNA<W9MDA
M2^D7R&6WW?-!C:5X)+9."XH L>%]6GOKO31]K^TF?3//OE\S=Y-QN08Q_!DF
M4;>,>7TXH HR6%M9^*+VWBGNIY+.PBO4B%TQ>242R,1C/\6T*1TQ@4 6$\5Z
MHVF6MTWV%!<7=K"I(SE9"%<860X(.2,GZCB@!+'7;_4=3T9I[FW2!Y[^UG5%
M(CE:*4HO5C@E5) YZGK0 SP3JTR-IVE&2W>VGM[N>/8"'3R[@+C.2""']!C;
M0!#:W=S)KLPBO+?4"9;L6UU!.?-A8;OW4T/=5^Z"#U X&[) +6D:]JES'X7L
MH+RRDDOM+-U-),C,Q9&@# 88<E9'_$ ],B@".#QGJKZ0VH/81*I,0*97=;EI
MMCAQYG15/4[>5.<#D %NQU;4Y_$VE"\GAAMYK.Z)C3E)&2:(*<AB-VT] 3C+
M<F@"]XD2TU/3[$)JWV)YY0;2ZAFQ\Y4E".<."0..01Q0!RS+=ZMI_B2XN(+B
MWU6P,,DD,<SA3)$-Y"<\HX'XAN>1P 7=!@^VZW>13M*;:]ECU6U_>.,0_,H4
M<^JHQ7_IJ1B@#O: "@ H * "@""2RM9;E+F2VA>X0861D!9?H>HZF@!J:=8Q
MR22)9P(\O+LL8!;G//'//- #UM+96D*V\0,C!G(0?,1T)]30 X00J5*Q("I)
M!"C@GJ?Q[T -@M+:UW_9[>*'>=S>6@7<?4XZT /EACGB:*:-9(V&&5QD'ZB@
M"-+*UBB6*.VA2-05"J@  /48]Z '"VMQ,DP@C$J+L5]HRJ^@/84 1_V?9>3+
M#]C@\J5MTB>6,.?4CN: !M/LGFBF>S@:6( 1N8P60#H >U #1I>GJDJ"PM@D
MQ!D41+A\=,\<T 6E4(H50 H& !T% $,MG:SS1S36T4DL1RCN@)7Z$]* '_9X
M?M'VCR4\[;M\S:-V/3/I0!%!I]E;(4M[.")=P;"1A1D=#QWH E$$*R>8L2!\
MD[@HSDXS_(?E0!)U&#0 P0Q!(T$:!8\;!M&%P,#'I0 P6MN(V06\81DV,NP8
M*\\'VY/'N: '>1#N#>4FX,7!VC(;&,_7!(S0 T6EL-N+>(;0JCY!P%.5'X'I
MZ4 .DMX97C>6%'>,Y1F4$J?4>E  ((0X<1(&!)!VC()ZG\: '(B1J%10JCH%
M&!0 V:W@N4"3PI*H(8!U# $=#S0 UK6W>Y2Y:"-IT&%D* LH] >HZT *UK;N
M,-!&1AAR@Z,<M^9Z^M "F"%I/,,2%^/F*C/&<<^V3^= "?9;<*5\B/:0P(VC
M!#'+#\3UH 9]@L_M8NOLD/VD# E\L;QQCKUZ<4 ,.EZ>UO\ 9S8VY@W;_+,2
M[=WKC&,T 3&UMR\3F",M",1G8,I]/2@!1!"K!A$@8;L$*,C<<M^9Y- #;>UM
M[.,QVT$<"$Y*QH%&?7B@":@ H * "@ H * "@#,OM9TVTU*'3[HR&Z>)[B)!
M;N^53[Q4A2,C(X!SR..: &6.MZ3J%S9/:%WEOK;[1!)]F==T61R6*\=1P2#S
MTH TTBCC9V2-5+G+$#&X^IH IVFK07ND'4H$E:(!SL"9<[200 .IR#TZT 78
MW\R)'"LNX X88(^HH BNKRVLHFEN9TB159R7;'"C+'\!S0!*CK(BNARK#(/J
M* &1VT$4C21P1H[?>95 )^IH @U'5+328(YKQW2.25(5*Q,_SNP51\H.,L0/
MQH A/B#2UAFD:ZV^1(L4B,C"17;&U=F-V3D8&.<\4 2VM_;ZBUU;H)4D@;RY
M5=60J2,C![\$<@T -@U+3([A-.@GC$B-Y*QKT#*H;9GID+SCKB@!5U3362>8
M74(2./S9'8X'EC/S9/5>#STH 5=2T\(SB9%,3K"5(PRL<;5V]<G(P.^10!'_
M &[IPN+.$3DM>.T<)$;%6=0Q9=V,!AL;@D'Y3Z4 6;^^M=+L)[Z]G6"UMT,D
MDC=%4=30!'-JMC;W8M9;E%F^0%?[N\D)D]MQ! SU/ H AMM>T^\O;BSADD,M
MON\PM!(B#:<-\Y 4X/H: +MO<Q740E@8M&>C8(#>XSU'N.* ,65=4@\77$D-
ME++8W5I#$)UE3;"ZO,6)4D$\.G0'I[4 <U#X9\0?V9>09GAFDTTV\[&^:3[5
M<DKB9"3\G ;GY3\P&/E% "W?A[Q"X OH7U2./5A*1#<B%IH!:-&K$Y7:V\J2
M!W!([4 37_AWQ!+IEE#*\UY.EDT*%+YHC;SY^61FX+X&!NP3\N<'<: )IM!\
M2+KS7<=YYMM+>VS31,^ 8T2/,B#^$[@X*]P1Z#(!V] '&)9Z^^D:KIGV.:)S
M>2SQ7!NE431-<%_+!4[D)C)7.!B@"K<:#KG]A21VD=Q$?MIGM;0WA;RH_*"A
M';<"5W[FPK_+D8)QB@#=\56&K:KH::=IS)%)<.JSR^:5$<8^9L$?-R0%XYPQ
M/% '.ZWH/BW4K&6:&X$6H?V5]D=!-B*>0EPY']T_=93VZ'J: -1=+UN/QD;S
M:9+=[@L9FN&VK!Y0 C$>1@AP3T(.<D@T 8F@Z%KVE>&DC;2IO[0AGM9) )TS
M<!#\^&\PCUZ[<YZ4 :DVF:G=^.++5I=*E%MY$0.94/D."Y;.''3<O0-F@#2\
M*Z?JFGM?I?B0Q.X:)IIC)(QR=V?F*XZ8("D]QP"0"WXGTZYU709;*TDDBEDE
MAR\4FQU42J6(/8[0: ..U/PYXEGM8UNH?M\BW\DC^4ZJ)(_*55;:SJ!DC)7/
M!)Z]: -#6-$\2?VD;O17$<4:)=Q022X!N0HC:-NOR&//MNYH W=1T>=?"0L+
M&:0WMI IM92^&,J#Y"Q/7)'.>H)SUH P=8\,ZLRK#9M<3_Z'Y=O-]L,1MKHL
MS-.^#\V2R] <;2,88T 2KX?UJ/QK<:KY@^R2W'.QV5V06JH,C?M*>8&.W;D$
M YQF@"WX(TG5](TY8-:;S[K[/ /M&_. J &+&3]T@G(X;=GKF@#1\5Z?=ZKX
M:N[*QP+B4H%R<#&]2<\CL#W% '/W^@>);>+38=,NTF33F:Z+22,GG.7)$2@L
MQ"A-R?,2,./[O !>NH->E7Q!86MM+ ;LF2UO3.H5?W:#;P2RG(;D#CK0!:\,
M:;>6#W[2PR6MI,Z&"UEN#.T9"X8[B3@$XX![9ZDT 82Z1XL%OK[SA)#JD+2Q
M11S\P2 X1.3@$H54E>,QY[\@&PVD-JVN:5K%WIDEK+ KB1'G!*D$&/[C%3_$
M?QYH J>&]$UFQU:":[,B[()$O97NVE6\E+*5=4/W< -V&,[0".: .QH * "@
M H * "@ H * "@ H * "@ H Y[Q3HM[JC:9<:=*L-U:W!#.3@B%T9),>X#!A
M[J* ,N'POJ-KIE_;11VL@%V@M(F=D5;59O,"\#@C>P (*X5<@C- "67AG5XW
MTOSGA_T-OF#.)4*B8L, J"I"8P5(YX(( H @L_"5]:Q8%I"'ET^\MIRK#YWD
ME#19]0!N'MNX[T 6I/#5P4C;[#"UQ'#8!9,KD/#(6<@]OE( /?&.!0!EKI5W
MJFI:U;/:@I=17UK#.TF63S&R/-0C. 5^0\X4^^: -&]\*:I>[G#V\$CVEO!$
M5<DV3QR,SLGR\[@5].5 /'0 DM/#5U9Z_#J(MHALU&YG=U(W&&2,@#W^;!Q[
M9ZT :NLVM[K&@62I;>7<&ZL[F2(N/D$<\<KKGC)PA ]\=* ,;4O">H7>K2:]
M$81?+=VUQ';&0[&2)'7:S8X8B5SG& 0OUH ZVS>ZE#R7%NMOG&V/<&8>[$<?
M@,].O.  8L]CJ,_B&*8Z=;K;0REHY%GP02NUI2H7)?:2HYX!/6@#&F\)ZM?:
M"-/E,5O+9Z4UA"XERL[YC(<@#(7]TO'7YF^I 'W'AS5[K5FU_8L=R+VWN%L3
M-D%(XGC8%L8W'S&([?*N2.P!8L_#VHV\>E,Z*9(]8N-1G42 B-9!-A%/<CS5
MSVX8^E $OB3PM?:IX6U*P36;RZN9H9TA$XA5=TB;%#;8Q\JY/O\ ,>2<8 '7
MWA9[V^CD26:(3R6TU[(SKF7R7WHN%'7( )&!CUH I7OAC5+^/4[96:U@NK6Y
MB=/M;O%-(\@9&523L^7<&P!RYX( H W?#MC>62WS7"R10S3!X+>2<S&)0B@_
M,2>K!C@'OGJ30!;?6+./6DTC=(UXT8E*I$S!5)(!8@8 )5ASZ>XR 59/%.D1
M6VJ7#7),>EMMN2(V)7Z#'S#.1QGE2.H- %RQU:RU&.XDLYUFC@959UY4YC60
M$'N"KJ<CUH S(?&6ESZ=;WT27;0W$BQP@6[%I"REA@8ST!- %L>(]**Z8RW6
M5U,_Z,=C?-QWX^7D@<XY8#J: &V_B?2;K47T^&YW74=T;1H]I!$@1G_+:C<]
M,@CK0 EOXFTZXMOM*?:%MR\21RO;NJ2>8X1"I(PP)(Y'8@]"* %/B;2Q;7UP
M99?)L9#%*_D/@N&V[5./F.X;<#)SCU&0!DWBBPMXH#)#?"6;>4MQ9R&4A,;F
MV;<X&5YZ?,!U- &I:74%]9P7=K*LMO.@DC=>C*1D$?A0!7N=7M+74[;3I&D-
MU<*614B9\*" 22!P,D<F@"E#XJTR:&]F5IA#9%Q(YA;!*L5(7C+'<" !U[4
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M/;6Y$T3.Q:6=8R>'7 "L#WR?I0!NV/VP6BB_:%KD%@S0J50C)P0"21D8XR:
M(1J*2:E<:=&KK/%$LF]HB4^8N!_Z >] %+2M7O=1\+C44M$EO<2!84;:KLKL
MH&3T!Q0!4C\42/?Q:?Y*F6XOI+2"X4'RI D/F,^/8ADQG[RGGT (CXKO9-$7
M5+;35DB5)%91)DO.DOE^2@ZY8AL-C'3UH T-<\0Q:/=V=GL=I[I9) 5B>0(D
M>W<Q502<;UXXZ]: *J^,+&75Q8Q3J8T\C?<>4[(S3?ZM01PN[*X+'JP !YP
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M'@#:S#&,'<>* '1^&;&&SM[6"6ZAB@C9$\N=@?FR6;/]XY//7F@">_T6"_6
M^=/!+"C1)+"X#[& #+D@\':OOD C!% %7_A$]+6ZCEB22*-! &@1\1OY)S$6
M'7*D#H1G SG% %NVT:"UNA<+/<NP9FVO,2I)ZDCN<<#/2@"H/">E_P!I?;&6
M1P)GN%@9LQ+*ZE7<#U()[XY) R: (H?!FDQ6$EFXGFC:!;9&DE):*)#E%5AR
M-IY!Z\#).!0!,OA>R6!E$US]J:Y^UF[WCS?-V;-W3'W/EQC&.U &EI]A!IEC
A%9VRD11YQN8L22<DDGJ2223[T 6: "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g268810dsp005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g268810dsp005.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M?!!4###Z%0?PH Y27X;Z_K,-EI?B7Q:-0T.SD5_(2S$<EQM^Z)'R?QQU^O-
M&]J?@TZI\0+3Q!/)"]E%I\EE+;.F3(')S[8P: *7P^^':^ M0UXV]WY]E?R1
1M;H0=\2KN^4GO][&?:@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
